Arecor chief financial officer to leave in July after five years
23rd Apr 2024 11:02
(Alliance News) - Arecor Therapeutics PLC on Tuesday said its chief financial officer has resigned to pursue new opportunities. Read More
(Alliance News) - Arecor Therapeutics PLC on Tuesday said its chief financial officer has resigned to pursue new opportunities. Read More
(Alliance News) - Arecor Therapeutics PLC on Tuesday announced a new partnership in the growing field of diabetes and obesity treatments. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Thursday celebrated a "strong commercial performance" for 2023, touting the first commercial product incorporating its platform Arestat. Read More
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Notes announcement from Inhibrx Inc and Sanofi SA that both companies have agreed Sanofi will acquires all assets and liabilities associated with INBRX-101. INBRX-101 is an optimised recombinant alpha-1 antitrypsin augmentation therapy, currently undergoing a residential trial treating patients with alpha-11 antitrypsin deficiency or AATD. INBRX-101 incorporates "a novel enhanced formulation" developed by Arecor using its patented Arestat technology. Arecor and Inhibrx entered a license agreement in December 2020. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Monday said it has expanded its hospital formulation collaboration with the pharmaceutical division of an unnamed partner. Read More
(Alliance News) - Arecor Therapeutics PLC on Monday announced a co-development and exclusive licence option agreement with an unnamed "leading global medical products company." Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it received a "milestone payment" from an unnamed pharmaceutical partner following the first commercial sale of its AT220 product. Chief Executive Officer Sarah Howell says: "The commercialisation of this product in Europe, the first to be launched incorporating our Arestat technology, is a significant milestone for Arecor and further demonstrates the strength of our Arestat platform and the value it can bring to our partners and ultimately patients." Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Monday said that it has increased the number of subjects for its ongoing Phase One clinical trial of its ultra-rapid, ultra-concentrated insulin candidate, AT278. Read More
Oxford Technology 2 VCT PLC - venture capital trust investing in quoted and unquoted technology companies - Net asset value of OT1 shares falls by 16% to 37.9 pence on August 31 from 45.3p on February 28. Similarly, NAV of OT2 shares falls to 20.5p from 25.1p, of OT3 shares to 23.6p from 33.7p, and of OT4 shares to 25.4p from 29.7p. No dividends are paid during the half year, nor are any shares bought back. Read More
(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Arecor Therapeutics PLC on Monday reported that its subsidiary Tetris Pharma Ltd has established an exclusive commercialisation agreement with Goodlife, a Dutch healthcare company. Read More
(Alliance News) - Arecor Therapeutics PLC on Thursday said it has signed an agreement with an unnamed "top 10 pharmaceutical company." Read More
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Announces "strong" progress across its business in the first half of 2023 amid progress for its in-house and partnered programmes. Cash as at June 30 falls 36% to GBP8.2 million from GBP12.8 million at December 31. Hails continued roll-out of Ogluo, a glucagon prefilled autoinjector pen used as a treatment for severe hypoglycaemia in children and adults living with diabetes. Glucagon is a hormone that stimulates glucose production in the liver. Arecor expects a second phase I clinical trial on diabetes 2-focused insulin candidate AT278 to complete in the fourth quarter of 2023. Read More
Arecor Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Enters into an agreement with a "leading biopharmaceutical company" to support the ongoing development of a biosimilar product. Says this revenue-generating collaboration follows an earlier technology partnership between the two companies, utilising Arecor's proprietary technology platform, Arestat, and formulation expertise. Read More